Foran JM, Cunningham D, Coiffier B, Solal-Celigny P, Reyes F, Ghielmini M, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000;11 Suppl 1:117–21.
Article
PubMed
Google Scholar
Chen Y, Wang M, Romaguera J. Current regimens and novel agents for mantle cell lymphoma. Br J Haematol. 2014.
Dreyling, M., et al. Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma (MCL) - summary of the 12 annual conference of the EUROPEAN MCL NETWORK. Leuk Lymphoma, 2014. p. 1–26.
Williams ME, Dreyling MH, Kahl BS, Leonard JP, O'Connor OA, Press OW, et al. Mantle cell lymphoma: report of the 2009 mantle cell lymphoma consortium workshop. Leuk Lymphoma. 2010;51(3):390–8.
Article
PubMed
Google Scholar
Dietrich S et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2014;25(5):1053–8.
Article
CAS
PubMed
Google Scholar
Qi CF, Xiang S, Shin MS, Hao X, Lee CH, Zhou JX, et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leuk Res. 2006;30(2):153–63.
Article
CAS
PubMed
Google Scholar
Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008;142(2):149–65.
Article
CAS
PubMed
Google Scholar
Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(−) mantle cell lymphoma. Blood. 2013;121(8):1394–402.
Article
PubMed Central
CAS
PubMed
Google Scholar
Chuang SS, Huang WT, Hsieh PP, Tseng HH, Campo E, Colomer D, et al. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. Pathol Int. 2006;56(8):440–8.
Article
CAS
PubMed
Google Scholar
Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106(13):4315–21.
Article
PubMed Central
CAS
PubMed
Google Scholar
Seto M. Cyclin D1-negative mantle cell lymphoma. Blood. 2013;121(8):1249–50.
Article
CAS
PubMed
Google Scholar
Bacher U et al. Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma. Exp Hematol. 2013
Soverini S et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood. 2003;102(5):1588–94.
Article
CAS
PubMed
Google Scholar
Sauerbrey A, Häfer R, Zintl F, Volm M. Analysis of cyclin D1 in de novo and relapsed childhood acute lymphoblastic leukemia. Anticancer Res. 1999;19(1B):645–9.
CAS
PubMed
Google Scholar
Bosch F, Campo E, Jares P, Pittaluga S, Muñoz J, Nayach I, et al. Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia. Br J Haematol. 1995;91(4):1025–30.
Article
CAS
PubMed
Google Scholar
Arber N et al. Increased expression of the cyclin D1 gene in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 1996;5(6):457–9.
CAS
PubMed
Google Scholar
Arber N, Hibshoosh H, Moss SF, Sutter T, Zhang Y, Begg M, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 1996;110(3):669–74.
Article
CAS
PubMed
Google Scholar
Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol. 2003;21(11):2085–93.
Article
CAS
PubMed
Google Scholar
Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 2002;62(20):5818–27.
CAS
PubMed
Google Scholar
Gladden AB, Diehl JA. Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem. 2005;96(5):906–13.
Article
CAS
PubMed
Google Scholar
Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007;55(1):1–14.
Article
PubMed
Google Scholar
Dengjel J, Decker P, Schoor O, Altenberend F, Weinschenk T, Rammensee HG, et al. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur J Immunol. 2004;34(12):3644–51.
Article
CAS
PubMed
Google Scholar
Kondo E, Maecker B, Weihrauch MR, Wickenhauser C, Zeng W, Nadler LM, et al. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res. 2008;14(20):6574–9.
Article
CAS
PubMed
Google Scholar
Dao T, Korontsvit T, Zakhaleva V, Haro K, Packin J, Scheinberg DA. Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS One. 2009;4(8), e6730.
Article
PubMed Central
PubMed
Google Scholar
Armstrong MJ, Robins GG, Howdle PD. Recent advances in coeliac disease. Curr Opin Gastroenterol. 2009;25(2):100–9.
Article
CAS
PubMed
Google Scholar
Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009;23(7):1320–8.
Article
CAS
PubMed
Google Scholar
Dougan, M, Dranoff G. The immune response to tumors. Curr Protoc Immunol. 2009. Chapter 20: p. Unit 20 11
Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 2007;220:129–50.
Article
CAS
PubMed
Google Scholar
Flacher V, Tripp CH, Stoitzner P, Haid B, Ebner S, Del Frari B, et al. Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. J Invest Dermatol. 2010;130(3):755–62.
Article
PubMed Central
CAS
PubMed
Google Scholar
Sancho D, Mourão-Sá D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, et al. Tumor therapy in mice via antigen targeting to a novel DC-restricted C-type lectin. J Clin Invest. 2008;118(6):2098–110.
Article
PubMed Central
CAS
PubMed
Google Scholar
Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood. 2010;116(13):2277–85.
Article
CAS
PubMed
Google Scholar
Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M, et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A. 2007;104(4):1289–94.
Article
PubMed Central
CAS
PubMed
Google Scholar
Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O'Bar A, et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood. 2010;116(10):1685–97.
Article
PubMed Central
CAS
PubMed
Google Scholar
Delneste Y, Magistrelli G, Gauchat J, Haeuw J, Aubry J, Nakamura K, et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity. 2002;17(3):353–62.
Article
CAS
PubMed
Google Scholar
Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol. 2002;2(2):77–84.
Article
CAS
PubMed
Google Scholar
Geijtenbeek TB, van Vliet SJ, Engering A, 't Hart BA, van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol. 2004;22:33–54.
Article
CAS
PubMed
Google Scholar
Brown GD. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol. 2006;6(1):33–43.
Article
CAS
PubMed
Google Scholar
Singh J, Garber E, Van Vlijmen H, Karpusas M, Hsu YM, Zheng Z, et al. The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci. 1998;7(5):1124–35.
Article
PubMed Central
CAS
PubMed
Google Scholar
van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67(1):2–17.
PubMed
Google Scholar
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245–52.
Article
CAS
PubMed
Google Scholar
Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184(2):747–52.
Article
CAS
PubMed
Google Scholar
Xu H, Zhao G, Huang X, Ding Z, Wang J, Wang X, et al. CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination. J Gene Med. 2010;12(1):97–106.
Article
CAS
PubMed
Google Scholar
Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol. 2007;178(7):4169–76.
Article
CAS
PubMed
Google Scholar
Flamar AL et al. Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells. AIDS. 2013.
Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265–77.
Article
PubMed Central
CAS
PubMed
Google Scholar
Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun. 2013;13:15.
PubMed Central
PubMed
Google Scholar
Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM. Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol. 2011;186(7):3847–57.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 1996;56(11):2479–83.
CAS
PubMed
Google Scholar
Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother. 2013;62(5):919–29.
Article
CAS
PubMed
Google Scholar
Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 2013;104(1):15–21.
Article
CAS
PubMed
Google Scholar
Bonifaz L et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002;196(12):1627–38.
Article
PubMed Central
CAS
PubMed
Google Scholar
Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004;199(6):815–24.
Article
PubMed Central
CAS
PubMed
Google Scholar
Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194(6):769–79.
Article
PubMed Central
CAS
PubMed
Google Scholar
Sadovnikova E, Jopling LA, Soo KS, Stauss HJ. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol. 1998;28(1):193–200.
Article
CAS
PubMed
Google Scholar
Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, et al. Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med. 2012;209(1):109–21.
Article
PubMed Central
CAS
PubMed
Google Scholar
Fan J, Hall P. On curve estimation by minimizing mean absolute deviation and its implications. Ann Stat. 1994;22(2):867–85.
Article
Google Scholar